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Executive Summary 
Novo Nordisk is a healthcare company and world leader in diabetes care.  With 
headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 
countries and markets its products in 179 countries. Since becoming one of the first 
companies in the world to produce an environmental report in 1994, Novo Nordisk 
has gained a reputation as a leader in the area of sustainability reporting. It has spent 
the last five years developing an ‘integrated’ reporting approach that seeks to measure 
social, environmental and financial performance within a single comprehensive 
document. 
 
The case study examines Novo Nordisk’s integrated reporting and how this reporting, 
explicitly linked to the balanced scorecard and other internal mechanisms, has served 
to embed sustainability into decisions taken at all levels in the company.  
Underpinning its approach is the company’s aim to achieve what it calls the ‘full 
integration’ of sustainability into business strategy, symbolized by the decision in 
2004 to publish a single ‘integrated’ annual report, which merged the previously 
separate financial and sustainability reports. Taking the concept of integration a step 
further, the case study examines internal management control systems and feedback 
mechanisms within Novo Nordisk that are integral to its embedding of accounting for 
sustainability within the company’s broader framework of sustainability management. 
These guidelines and systems are called the Novo Nordisk Way of Management.   
 
A striking feature of Novo Nordisk’s approach is its desire to manage values and 
principles as well as more tangible commitments and outcomes.  Fostering a 
‘mindset’ to embed sustainability in the organization is potentially a very effective 
mechanism, although its potential is, in the view of the authors, still to be fully 
realized. 
 
Novo Nordisk has several key lessons to share from the last two decades over which it 
has developed its approach to embedding and reporting sustainability:  
 
• While integrated reporting serves as an accountability mechanism for the 
organization as a whole, the embedding of Novo Nordisk’s sustainability 
strategy within the organization is dependent on a wider range of internal 
systems, values, commitments and principles. The company has developed a 
‘Way of Management’ that encompasses elements of corporate governance, 
employee culture, specific management tools, and rigorous performance 
measurement methods. In this way, integrated reporting may be viewed as just 
one facet of a broader approach that offers the potential to strengthen further 
and ‘embed’ a sustainability mindset within the organization. 
 
• Stakeholder engagement is core to the identification of issues that are or could 
become material and to the development of a sustainability strategy.  Novo 
Nordisk has adopted a pro-active approach designed to identify and address 
issues of concern. 
 
• The principles and guidelines underpinning the sustainability strategy need to 
provide control and common direction but be flexible enough to accommodate 
national and cultural diversity as well as multiple stakeholder expectations.  
This is of particular importance in a diverse, international organization. 
 
• Mechanisms such as the balanced scorecard and the linkage of non-financial 
targets to reward packages enable employees to see a direct connection 
between the stated social and environmental commitments in the company’s 
overall strategy and their own role within the organization. 
 
• The use of both quantitative (financial and non-financial) and qualitative 
feedback methodologies provide a rounded perspective on how sustainability 
is being embedded at all levels within the organization.  
 
 
 
Introduction 
In 1994, the Danish pharmaceutical company Novo Nordisk became one of the first 
companies in the world to produce an environmental report. Since then, the company 
has continued to expand and develop its voluntary disclosures and has gained a 
reputation as a leader in the area of sustainability reporting. Although Novo Nordisk 
has not yet adopted the Connected Reporting Framework, it has spent the last five 
years developing an innovative and in some respects more ambitious approach, which 
it calls ‘integrated’ reporting, that seeks to measure social, environmental and 
financial performance within a single comprehensive document. Underpinning this 
approach is Novo Nordisk’s bold aim to ‘fully integrate’ sustainability into business 
strategy. The pursuit of what the company calls full integration is not limited to the 
development of new disclosure practices: instead, Novo Nordisk has developed a 
‘way of management’ that encompasses corporate governance, employee culture, 
specific management tools, and rigorous performance measurement methods. In this 
way, sustainability reporting may be viewed as just one element of a broader 
approach that may offer the potential to further strengthen and ‘embed’ a 
sustainability mindset within the organization. The purpose of this chapter is to 
examine the background and development of integrated reporting at Novo Nordisk 
and to explore the extent to which the company’s goal of full integration and its use of 
reporting and other control systems has succeeded in making sustainability an 
embedded feature of the organization.  
 
Context & Background 
Novo Nordisk is widely regarded as a leader in diabetes care, employing over 27,000 
people across 81 countries. A controlling share in Novo Nordisk is owned by the non-
profit-making Novo Nordisk Foundation, which means that the company has a degree 
of operational freedom by comparison with the rest of the pharmaceutical industry, 
and is protected from the threat of possible takeovers. In 2000, Novo Nordisk was de-
merged from its enzymes business Novozymes, and the two companies have 
remained separately listed since then. Novo Nordisk Foundation effectively owns a 
controlling interest in both companies, and acts as a stable platform for the two 
operating companies. A holding company, Novo A/S, creates a link between the 
Foundation and the two operating companies: importantly, Novo A/S has the voting 
majority at the Annual General Meeting of Novo Nordisk. This has given the 
company relative freedom to choose its strategic direction, not least in relation to the 
integration of sustainability into business strategy. Novo Nordisk was founded in the 
1920’s with a specific mandate to help people, and this mandate continues to 
influence the company’s strategic direction. In 2004, Novo Nordisk amended its 
Articles of Association to explicitly commit itself to ‘strive to be economically viable, 
socially responsible and environmentally sound’. This decision was endorsed by the 
company’s investors, who regard the company’s strategic direction as being 
particularly compatible with the company’s business model: 
 
“For the majority of our investors, financials are still the most important – 
R&D spend, sales prospects etc. But we do benefit from investors taking a 
long term perspective. It’s not just our unusual capital structure – it’s the fact 
that a lot of what we do, our business model, has a ten year development lead 
time. So a lot of our institutional investors understand our concern with 
sustainabilty. They see the sustainability issues as a fundamental perspective 
on Novo Nordisk. In other words, we are less risky.” (Corporate Vice-
President, Head of Investor Relations) 
 
The origin of the company’s modern interest in sustainability may be traced to 
specific incidents over the last three decades, where the company suffered criticism 
from external stakeholders and associated negative media coverage. The first of these 
incidents occurred in the early 1970s, when the company faced allegations from the 
then consumer advocate Ralph Nader who claimed that new detergent enzymes were 
affecting the health of the American employees involved the production process. The 
reputational damage caused by this episode caused sales in the company’s U.S. 
market to fall by half, and as a consequence, management attention became focused 
on the vulnerability of the business to public opinion.  
 
In response, the company sought to better recognize the broad set of stakeholders to 
whom the organization owed a responsibility and to explore the impact of that 
learning curve on the company’s strategic direction. In 1990, when the company 
faced the prospect of further negative media attention in relation to its use of 
genetically modified organisms, Novo Nordisk was this time ready to initiate a more 
pro-active form of stakeholder engagement, designed to identify and address issues of 
concern. The company successfully persuaded those involved in making the 
allegations to revise and correct them, and in so doing, limit the extent of negative 
media coverage. More importantly, however, the engagement also led to the 
recruitment of one of the principal authors of the allegations, John Elkington, to 
undertake a review of the company’s business practices in relation to the 
environment. A year later, the company launched its first sustainability strategy, 
focused primarily on the environmental issues of concern at the time. 
 
Since then, stakeholder engagement and trend analysis have become essential tools to 
enable the company to identify new issues which are (or could become) material. The 
company uses what it calls a ‘learning curve’ - a tool that aligns the process of 
defining materiality with integration into business practices (see Figure 1 below). 
Emerging issues that are identified as relevant and potentially material are included at 
the beginning of the learning curve. The company then reviews its implications for 
Novo Nordisk’s long-term business: often, an independent expert will be 
commissioned to undertake this review. The review is considered by the Executive 
Management team, comprising the Vice Presidents of seven corporate divisions. 
Strategies are then developed for those issues that are deemed material. To manage 
the strategy going forward, data, indicators and targets are identified. Over time, as 
management of the issue gradually develops, the strategy may be revisited and 
reappraised.  
Figure 1: Novo Nordisk’s Current Sustainability Agenda  
Level of integration/ 
organizational learning Stage of learning curve Current strategic areas  
 
High Revisit strategy  
Diversity 
Environmental management 
Occupational health & safety 
 
Full business integration globally 
Employee wellbeing 
Access to health 
Bioethics 
 
Embedding in the organization 
Business ethics 
Climate action  
 
Develop indicators, data & 
targets; stakeholder dialogue 
Diabetes in children 
Responsible sourcing 
 Undertake review; formulate 
strategy & action plan Transport emissions 
 Issue identification & materiality 
assessment 
Maternal health 
Diabetes outcome data 
Low 
Trendspotting & stakeholder 
engagement Health technology assessment 
 
One of the most visible early outcomes of the new strategy was the company’s 
publication of environmental reports. Novo Nordisk produced its first environmental 
report in 1994, a year ahead of Danish legislation requiring that certain companies 
disclose information about their environmental impacts. In 1997, Novo Nordisk 
commissioned an independent expert to undertake a review of the company’s human 
rights, and by 1998, the first social report was published. In 1999 both social and 
environmental reports were merged into one document and in 2001, Novo Nordisk 
explicitly adopted the Triple Bottom Line (TBL) approach to sustainability reporting, 
in which social and environmental impacts were measured alongside economic 
performance. In 2003, for the first time, the Sustainability Report was published at the 
same time as the Annual Financial Report and distributed to shareholders. Novo 
Nordisk believed that this move was well received by shareholders and other 
stakeholders, because the two documents together provided a more comprehensive 
overview of the company’s performance, progress, positions and strategic initiatives. 
As a result, Novo Nordisk took the decision to fully merge its financial report and its 
sustainability report into one inclusive, integrated report. According to the company’s 
official documentation, 
 
“the aim is to drive business performance and enhance shareholder value by 
exploring the interactions between financial and non-financial objectives. This 
entails alignment of key priorities, target setting and definition of key 
performance indicators, in consultations that involve internal and external 
stakeholders.” (Novo Nordisk Annual Report, 2008) 
 
The 2004 Annual Report was the first such integrated report, and was compliant with 
International Financial Reporting Standards (IFRS); the AA1000 Framework; the 
Global Reporting Initiative (GRI) Sustainability Reporting Guidelines; and the United 
Nation’s Global Compact. Novo Nordisk does not use the Connected Reporting 
Framework, but there are numerous similarities between the Framework and the 
company’s published reports. Indeed, it is in many ways more comprehensive than 
the Framework, in terms of the wider range of non-financial indicators that are 
included. However, unlike the Connected Reporting Framework, Novo Nordisk’s 
non-financial indicators are not currently financialized. 
 
It is important to emphasize that sustainability reporting at Novo Nordisk is one 
element of a wider strategic approach that has gradually evolved since the early 
1990s, that is intended to integrate sustainability into business practices. Of key 
importance here are the economic, social and environmental ‘commitments’ 
underpinning the integrated reporting approach. Whilst the use of integrated reporting 
serves as an accountability mechanism for the organization as a whole, attempts to 
further embed the company’s stated commitments within the organization have been 
driven by a number of other innovative developments. For example, at the corporate 
governance level, the explicit adoption in 2004 of these commitments in the 
company’s Articles of Association was especially significant. In addition however, 
and of particular concern within this chapter, are internal control and feedback 
systems that together comprise a larger formal framework of management guidelines 
and systems within the organization. The next section introduces some of these 
elements in more detail. 
 
The Novo Nordisk Way of Management 
In 1997, Novo Nordisk introduced a comprehensive formal management framework 
known as the Novo Nordisk Way of Management (the ‘Novo Nordisk Way’). It 
comprises a set of principles and guidelines designed to help embed and 
operationalize its vision. The Novo Nordisk Way was originally set up as a 
framework for managers in the company’s foreign subsidiaries to better understand 
and align to ‘the way we do things’, yet allow a degree of flexibility at 
local/divisional management level. It was intended to provide sufficient control over 
global company operations and ensure common direction (including sustainability), 
yet at the same time allow enough malleability to absorb challenges arising from 
diversities in national and cultural aspirations as well as multiple stakeholder 
expectations. 
 
The Novo Nordisk Way consists of three main components: vision, charter, and 
policies. The vision establishes broad direction and sketches out a general theme of 
striking a balance between commercial endeavours and behaving in a responsible 
manner. Of particular interest here is the second component, which is the charter (see 
figure 2 below). The charter describes an overall framework of guidelines for all 
corporate activity, based on three main elements: values, commitments, and 
fundamentals. Values are intended to further define the general ethos outlined in the 
vision, while the fundamentals set out in more detail a number of management 
principles. The commitments mirror the three dimensions of the TBL approach 
described earlier, and the commitments reflect those defined in the company’s 
Articles of Association. Finally, the third element of the Novo Nordisk Way is a set of 
13 policies on specific operational issues, covering bioethics, business ethics, 
communications, environment, finance, global health, information technology, legal, 
people, health & safety, purchasing, quality and risk management. To link the 
operational policies with the overall TBL approach, a governance structure known as 
the ‘TBL Leadership Forum’ has been established. This body has a cross-functional 
remit, spanning the work of a number of high-level committees with specific 
responsibility for overseeing the operational policies identified previously, and with 
an aim to secure implementation and development of Novo Nordisk’s TBL strategy. 
 
Figure 2: The Novo Nordisk Charter 
 
Values 
• Accountable, ambitious, responsible, engaged with stakeholders, open & honest, ready for change 
Fundamentals 
• Business units share and use better practices 
• Units are clear with regard to their respective accountabilities and decision-making powers 
• Units have an action plan to ensure improvements in both business performance and the working 
climate 
• Teams and individuals have up to date business and competency targets, against which they 
receive timely feedback on performance 
• Units have action plans to ensure team and employee development, as required 
• Managers establish and maintain procedures in their units to align and adhere to relevant laws, 
regulations and corporate commitments 
• Units and individuals know how to create customer value 
• Managers explain to others the actual use and added value of any reports they require 
• Managers enable employees to easily and speedily turn attention to any customer related issues 
• Managers and units actively support inter-unit projects and other relevant working relationships 
• Individuals continuously seek to improve their work 
Commitments 
• Financial responsibility: growth, value creation, compliance with standards 
• Environmental responsibility: improve performance, integrate into strategy, maintain open 
dialogue and reporting transparency, support ICC Charter for Sustainable Development & UN 
Convention on Biological Diversity 
• Social responsibility: improve performance, integrate into business, dialogue, reporting 
transparency, support UN Universal Declaration of Human Rights 
 
The charter forms the central mechanism in the Novo Nordisk Way, since it defines 
both a framework for corporate activity as well as the feedback and control 
mechanisms needed to measure and manage such activity. Three key dimensions of 
action: values, fundamentals and commitments, are supported by a number of ‘follow-
up methodologies’. Those relevant to the management of sustainability are shown in 
Figure 3: 
Figure 3: The Novo Nordisk Charter:  
Follow-up methodologies relevant to sustainability strategy 
 
Values 
Commitments   Fundamentals 
      
Triple Bottom Line 
management 
Balanced scorecard Facilitation 
Focus on aggregated non-
financial reporting 
Focus on all aspects of 
divisional and business unit 
performance 
Focus on embedding values and 
fundamentals in business units 
 
Headline strategic areas: 
 
Environmental: 
• Emissions  
• Resource intensity  
• Regulatory compliance  
 
Social: 
• Living our values  
• People 
• Health & safety 
• Access to health 
• Business ethics 
• Company reputation 
• Quality 
 
Critical success factors 
include: 
• Ensure corporate 
responsibility 
• Ensure an engaging 
culture 
• Ensure people 
development 
• Ensure customer 
satisfaction 
• Ensure company 
reputation 
• Ensure effective sourcing 
 
 
Key outcomes: 
 
• Typically 5 
recommendations per 
business unit facilitation (3 
year cycle, 60 facilitations 
per year) 
• Consolidated report based 
on all recommendations 
given to executive 
management 
• Overall trends used to 
inform strategy/reporting 
 
TBL management typically operates at an aggregated level across all business units, 
enabling the company as a whole to measure its performance against the economic, 
social and environmental commitments enshrined in the corporate charter and Articles 
of Association. In addition, the headline non-financial indicators relevant to 
sustainability are used to inform the development of a corporate balanced scorecard, 
which is designed to assess overall performance of each corporate division and is 
cascaded down to both business unit level as well as to individual senior managers’ 
targets. Hence, a mechanism exists to link individual managers and business units to 
the social and environmental dimensions of the company’s overall strategy. The 
facilitation methodology, in contrast to TBL reporting and the balanced scorecard, is 
designed to focus on the underlying principles guiding corporate behaviour: the 
values and fundamentals in the corporate charter. Rather than performance indicators, 
the facilitation methodology is based on more qualitative data gathering, especially 
interviews.  
 
While each feedback methodology focuses on a specific dimension of the company’s 
management charter, taken together the different elements in the Novo Nordisk Way 
act to reinforce each other: 
 
“There’s no way that we’d be where we are solely based on our reporting 
system. It’s got a lot to do with the corporate governance structure” (Director, 
Global TBL Management). 
 
We will now examine each of these three feedback mechanisms in more detail. 
 
Triple Bottom Line (TBL) Management 
TBL reporting was formally adopted by Novo Nordisk in 2001. TBL reporting 
measures the extent to which company is progressing in relation to its stated 
economic, social and environmental commitments. Figure 4 below, extracted from the 
2008 Annual Report, highlights the main strategic areas, or ‘non financial accounting 
policies’ for which it currently sets indicators and targets.  
 Figure 4: Headline TBL indicators & targets (Novo Nordisk Annual Report 2008) 
 
 The TBL approach has been steadily developed and refined since its introduction. For 
example, one of the most visible recent examples of this has been the decision to 
present its headline non-financial results directly alongside its financial results. In 
addition, in order to manage the gradual inclusion of social as well as environmental 
strategic objectives, the company has gradually increased the number of non-financial 
indicators it uses. Having initially focused mainly on the environmental concerns of 
the 1990s, it has sought to develop more indicators in the area of social responsibility, 
with a focus on areas such as access to health and business ethics.  
 
Just as in the 1990s, the emergence of these issues as strategic areas of importance 
may be attributed to the influence of external stakeholders, and the pro-active 
management of stakeholder concerns using the corporate learning curve approach 
described earlier. In 2001, Novo Nordisk jointly undertook legal action with 38 other 
pharmaceutical companies against the South African government for violating 
intellectual property agreements, particularly in relation to AIDS medications. 
Although Novo Nordisk does not manufacture such products, it participated in the 
court case because it believed that the agreement balanced the rights of the 
pharmaceutical industry against the needs of developing countries. The case caused 
public concern in Denmark, and as part of its response to the backlash, the company 
invested a number of new initiatives designed to improve access to healthcare in 
developing countries. Currently, the company sets specific TBL targets in relation this 
issue in terms of (1) the number of developing countries it sells insulin products to at, 
or below, cost price, as well as (2) the number of healthcare professionals and 
diabetes sufferers it has trained or treated. A further episode of negative public 
scrutiny in 2005 centred on the role of company sales representatives in negotiating 
inflated prices of products destined for Iraq as part of the ‘Oil for Food’ programme. 
Like the 2001 episode involving South Africa, the incident also influenced the 
ongoing development of TBL management, and the company now includes a specific 
target for the number of sales & marketing representatives it will train in business 
ethics.  
 
More fundamentally, however, the company’s vision of ‘full integration’ extends well 
beyond issues of measurement scope and report presentation:  
 
“Eventually we want to talk in terms of ‘full integration’. We want there to be 
one of everything - one performance measurement system, one management 
control system, and one audit system.” (Director, Global TBL Management). 
 
Not withstanding the apparent simplicity of this general ambition to create ‘one of 
everything’, as well as strong and collective support towards the corporate strategy, 
staff recognized the cultural as well as technical implications of the task: 
 
“I personally think that there are some barriers to full integration, and 
barriers in our (non-financial data management) department towards the 
financials. I see challenges ahead in relation to a common understanding 
and language between the financial and the non-financial people, a whole 
cultural thing, a way of thinking. This is about two different worlds, but of 
course we see the purpose of each other. We’re just not always on the same 
page in terms of what is material.” (member of Non-Financial Data 
Management).  
 
In its pursuit of full integration, Novo Nordisk embarked in 2008 on a process of 
structuring the control environment of non-financial reporting. The ambition of this 
innovative work, to be phased in over a number of accounting cycles, is to gradually 
achieve full alignment with the control environment of financial reporting. The next 
section explores the early stages of this work in more detail. 
 
‘Sarb-Oxing’ the Non-financial Control Environment 
The US Sarbanes–Oxley Act lays down requirements for documenting and reporting 
on the effectiveness of internal controls for financial reporting. Listed on the New 
York Stock Exchange, Novo Nordisk is obliged to meet these requirements and first 
did so in 2005, one year ahead of the deadline, and one of the first non-U.S. 
companies to do so. As part of its objective of full integration, Novo Nordisk has 
begun the task of applying the principles of the Sarbanes-Oxley Act to all of its 
reporting, to ensure that are no material weaknesses in internal controls that could 
lead to a material misstatement in its non-financial reporting. For the 2008 annual 
report, the internal audit committee took the decision to introduce what some staff 
informally referred to as “Sarb-Oxing”. The aim was to phase in, over a number of 
accounting cycles, the same rigour, sophistication and credibility of existing financial 
systems to non-financial metrics. Over time, the process for gathering data for the 
headline non-financial indicators would eventually mirror the approach taken for 
putting together headline financial highlights on the opposite page of the annual 
report. The process of emulating best practice even stretched to adoption of the same 
methods for filing, archiving, documentation, and using the same reporting templates 
as used at operational levels.  
 
Beginning such a task for non-financial reporting was a huge undertaking. The TBL 
data management team drafted in the Sarbanes-Oxley Consulting Team (previously 
responsible for applying the Act to financial information) to help them begin to apply 
the same rigorous tests and assurances to non-financial data. Significantly, the general 
view of those involved in this collaborative work as extremely positive: the difficulty 
involved in this extremely challenging task was eased considerably by what appeared 
to be an remarkable willingness to collaborate across different business functions and 
for the good of the overall business: 
 
“This is a company that embraces change, but I also think this has high focus 
within Novo Nordisk. People of Novo Nordisk are proud of what they are 
doing, proud of the triple bottom line, proud of the annual report, and so on. 
And they are actually interested in making this better. So generally the 
project for integration has been taken positively. There’s a general concern 
that the numbers are correct. People will do what they need to do to achieve 
this. They don’t want to report a wrong number on say animal testing or 
something like that.” (Member of the Sarbanes-Oxley Consulting Team). 
 
The Sarbanes-Oxley team needed to familiarize themselves quite quickly with the 
non-financial metrics of the business, and there was a learning process to go through. 
Overall, however, team members argued that there was much similarity between the 
financial and non-financial metrics processes:  
 
“It was actually the same risks that we needed to cover, and kind of the same 
controls that we needed in place. The system, the controls and many of the 
procedures are actually quite similar. So, I don’t think the two things are so 
far apart.” (Member of the Sarbanes-Oxley Consulting Team).  
 
Because of its aggregated, long-term basis, the TBL reporting approach is not directly 
used to assess and monitor the performance of individual business units. This is a task 
that is instead managed through the balanced scorecard. The headline non-financial 
indicators derived from the company’s key strategic aims in relation to sustainability 
issues are themselves used to inform the development of key performance indicators 
within the balanced scorecard. The next section explores the relationship between the 
aggregate measures used to drive TBL reporting and the use of the balanced scorecard 
to embed strategic priorities in individual business units. 
 
The Balanced Scorecard 
In contrast to external stimuli that originally helped motivate the company’s interest 
in sustainability issues, the introduction of balanced scorecards was instead rooted in 
more immediate operational concerns. Balanced scorecards have been used in Novo 
Nordisk since 1996, and were originally introduced by the Finance Department as part 
of instilling better local financial management throughout the business units. The 
Novo Nordisk scorecard begins at the organizational level, and is reviewed annually 
to take account of the key strategic aims and associated non-financial performance 
indicators used to produce the company’s overall TBL reports. The scorecard is then 
cascaded down, first to the divisional level of Executive Vice-Presidents. This is 
further cascaded down to the Senior Vice-Presidents at the business unit level. There 
is no formal requirement to cascade the balanced scorecard below business unit level, 
although some business units voluntarily choose at least to cascade down particular 
KPIs in sub-units such as a plant. In general, long-term objectives and goals used in 
TBL reporting are broken down into short-term targets in the balanced scorecard. 
However, while employee performance is generally tied to short-term goals, some 
managers, particularly those at executive level, are measured directly on achievement 
of long-term goals which the company publicly reports against. 
 
As part of their remuneration package, individuals are rewarded for performance that 
meets or exceeds the non-financial targets in the balanced scorecard. Overall progress 
is tracked against the targets for headline non-financial indicators in the annual report. 
These include socio-economic impacts such as job creation, the ability to manage 
environmental impacts and optimize resource efficiency, and social impacts related to 
employees, patients and communities.  
 
The balanced scorecard currently has a total of 24 critical success factors, grouped 
under the four headings of Customers & Society, Finance, Business Processes, and 
People & Organization. In broad terms, responsibility for meeting balanced scorecard 
objectives is cross-functional, meaning that all divisions will to some extent be 
required to contribute to the overall social and environmental targets set out in the 
TBL reports. Our investigation included sight of the use of balanced scorecards in 
‘Responsible Sourcing’. A key aim of this business unit is to integrate ethical practice 
into the company’s supply chain. Senior supply chain managers spend a great deal of 
their time assessing how ethical Novo Nordisk’s suppliers are, which is an enormous 
task. A more immediate objective is to undertake a mapping of ‘risk areas’ amongst 
its supplier base; which in some instances has led to Novo Nordisk breaking its ties 
with a particular supplier.  Several staff in the responsible sourcing area highlighted 
again that this was as much about ‘doing things the Novo Nordisk way’ than anything 
else: 
 
“Of course there is a reputation protection part. But I see this as my 
responsibility – and I explain to my people – that we have a responsibility to 
ensuring a sustainable supply of material” (Head of Procurement – Direct 
Spend) 
 
Senior managers in the procurement area were working hard to articulate and instil 
amongst suppliers that it made good business sense, promised value creation, to go 
about their work in a sustainable way: 
 
“I think this is an evolution in the whole corporate social responsibility 
agenda, from being a side-function, or an NGO-type function to the company, 
towards being a more integrated part of value creation” (Director, 
Responsible Sourcing). 
 
Through their balanced scorecard, the Head of Procurement for ‘direct spend’ (i.e., 
the materials which are used to make the company’s finished products) is accountable 
for two KPIs relating to supplier risk management; these KPIs also influence how his 
bonus is calculated. Moreover, he pushes such targets to the management level below 
him, and they too have bonuses that are partly calculated on KPIs such as those 
relating to responsible sourcing. There are ten bonus-linked KPIs in total, of which 
and half are non-financial. 
 
The ultimate aim is to link the overall non-financial TBL indicators and associated 
long-term targets to short-term equivalent KPIs within the balanced scorecard:  
 
“We shouldn’t just report on a number just because we can. It should be 
anchored and there should be a goal. If management don’t have a focus on the 
number, then we have a risk. We have a risk that it’s not the right number 
being reported or that it’s incorrect. So now, if an indicator is in the Annual 
Report, its equivalent will be in the Balanced Scorecard, or vice-versa” 
(Member of Sarbanes-Oxley Consulting Team).  
 
However, there remained a number of obstacles in the way of this aim in respect of 
aligning non-financial reporting mechanisms to the quarterly system of financial 
reporting. Firstly, full alignment between the financial and non-financial reporting 
mechanisms will require capturing the data for non-financial measures on a quarterly 
basis; for many such measures this has never been the case.  Secondly, there were 
issues relating to the consistency of KPI targets: 
 
“We could be more structured in the way we define our KPIs – not just today 
but 3 or 5 years ahead. Long term targets – stakeholders can follow them and 
establish proper expectations. In the past we were less consistent. Those issues 
concern any of our KPIs – it could be CO2, it could be how we are dealing 
with culture.” (Senior Vice-President, Facilitation & Group Internal Audit) 
 
There is also an issue in respect of the quality of information being used to feed not 
only the balanced scorecard but other reporting tools also. For example, referring 
again to responsible sourcing, for this Novo Nordisk relies almost entirely on data 
provided by the (external) supplier. And, though it was acknowledged that some key 
and usually longer-established suppliers were very accommodating with the provision 
of information relating to their ethical (or not) ways of working, it was proving to be a 
major challenge to draw the necessary information from some suppliers. In this 
respect, at least where it is appreciated, Novo Nordisk will usually offer to advise 
their suppliers as to how to make improvements in its practices and also now has a 
handbook for its suppliers on responsible sourcing. 
 
While the balanced scorecard includes success factors relating to employee culture 
and development, these strategic aims are also reflected in the third key feedback 
methodology used in the Novo Nordisk Way: facilitation. The next section outlines 
the significance of this methodology for embedding sustainability into business 
practices. 
 
Facilitation 
Originally introduced in 1996, facilitation is a key mechanism by which Novo 
Nordisk seeks to ensure that the stated values and fundamentals of the company 
charter - the underlying principles supposed to guide corporate behaviour - are being 
practiced across the organization.  
 
“We have a set of values, of systems, but I think all companies have those 
things, that’s not unique. What is unique is that Novo Nordisk is actually 
following up on it in every department, every unit within the company. And 
then we report back to the units, we give them a rating and also some actions. 
You don’t see that in many companies - normally you have to please your 
shareholders, but we are saying, we have to please our stakeholders.” (Senior 
Vice-President, Facilitation & Group Internal Audit) 
 
Facilitation is undertaken by a small team of highly experienced staff with broad 
expertise, usually ‘hand-picked’ from senior managerial positions within Novo 
Nordisk. Staff work in pairs on a three-year cycle to review all the business units.  
The facilitators’ tasks include: assessing the extent to which a business unit is 
performing in compliance with the values and fundamentals of the company charter; 
where necessary, assisting business units to achieve compliance with such 
requirements and rules by issuing a number of recommendations to unit managers; 
and identifying and sharing ‘best practices’ across the whole organization by collating 
evidence from the 60 or so facilitations undertaken every year and producing a 
consolidated report which is submitted directly to executive management. 
 
The methodology of the facilitators in all the above tasks is much less quantitative in 
approach than TBL reporting or balanced scorecards: in particular, evidence is 
gathered through face to face interviewing of business unit managers and other 
employees.  
 
“Facilitation is not based on data – it’s based on interviews. You can go into 
a unit and select maybe 25% of the people there to speak to. You ask 
questions, you have a dialogue, to try to find out what is working and what 
isn’t. You might find for example, maybe the unit has a good strategy, the 
management team know exactly what they would like to do, but they are not 
communicating this to the rest of the organization, so they’re not aware of 
where you’re heading and you end up with a mismatch of expectations. 
Another example could be that management are not good at staff development, 
they are too focused on the current task. So based on the interviews we will 
come up with actions.” (Senior Vice-President, Facilitation & Group Internal 
Audit) 
 
The process is designed to be as constructive as possible to result in an agreed plan 
for business unit improvements. Each facilitation results in around five ‘actions’ 
being given to unit managers. Follow-up phase enables facilitation staff to monitor 
implementation of recommendations issued. Over the course of a year, 50 to 60 
facilitations take place, resulting in 250 to 300 actions being given in total to unit 
managers. In order to assimilate the implications of this for the company as a whole, 
the facilitations team also produces a consolidated report that is submitted to 
executive management and the board of directors of the company. The consolidated 
report considers the areas in which most actions are being recommended, as well as 
the overall trends from one year to the next.  
 
The consolidated report provides a link between the performance of individual units 
and the organization as a whole. In some ways this linkage echoes the relationship 
between the TBL indicators used in the annual report and the KPI used in the 
cascading balanced scorecards. Importantly, however, the operation of the qualitative 
facilitation process is generally seen a largely separate, parallel exercise by 
comparison with the much more quantitative metrics of integrated reporting and 
balanced scorecards: 
 
“It has no impact on facilitators whether we have integrated reporting. We 
don’t use non-financial data. Of course we ask the units about their 
management of environmental and social commitments, but as long as they 
are aware of their responsibilities, that’s all we ask. I don’t think our work 
impacts on the development of non-financial indicators, but we have our 
consolidated reports that identify trends. For example, let’s say we might 
discover staff engagement levels are going down across the organization. Or, 
we might find we have no focus on training. And then you might set targets 
using the non-financials. Also, when we set up balanced scorecard targets for 
the next year, we may use the consolidated facilitation report. We could use 
KPIs or balanced scorecard targets, e.g. number of days or actual spend on 
training. It’s possible, but it’s not a direct link. Our work is still only a small 
input to TBL management, because there are other stakeholders that have 
things that we might like to put into it too.” (Senior Vice-President, 
Facilitation & Group Internal Audit) 
 
The next section concludes the chapter by exploring the extent to which the three 
main control systems outlined above contribute to the ‘embedding’ of sustainability in 
Novo Nordisk. 
 
 
Full Integration at Novo Nordisk: Towards the Embedding of Sustainability 
In this chapter, we have examined the company’s pursuit of ‘full integration’ by 
outlining the development of Novo Nordisk’s sustainability strategy, as well the 
formal systems and controls that have been developed to measure and manage 
strategic priorities. At the corporate governance level, Novo Nordisk has explicitly 
committed itself to being “socially responsible” and “environmentally sound” and has 
sought to deliver on this commitment by means of an unusual combination of formal 
control systems that emphasize both scope and rigour in quantitative performance 
measurement as well as the importance of underlying values and principles of 
management. By comparison with its peers, Novo Nordisk’s achievements in relation 
to the development of its sustainability strategy are impressive, but the company also 
recognises that this is an ongoing, incremental task, and the senior managers we spoke 
to were quite open and honest about the challenges the company faces.  
 
 
In response to external pressures, the company has gradually developed a systematic 
mechanism to integrate stakeholder management into strategic development. 
However, Novo Nordisk’s sustainability strategy is also informed by, and dependent 
upon, a wider internal assemblage of systems, values, commitments and principles 
that together comprise ‘the way we do things’. This formal internal machinery, known 
as the Novo Nordisk Way of Management, consists of such tools as triple bottom line 
reporting and the balanced scorecard. In the same way as the emphasis on stakeholder 
management was triggered by external events, it is interesting to note that the impetus 
behind the development of some of these systems was rooted in rather conventional 
concerns such as expansion into overseas markets (in the case of facilitation) or 
internal financial control (in the case of the balanced scorecard). Nevertheless, the 
pursuit of full integration is perhaps most evident at this level, particularly in relation 
to the evolution of the annual report. The current focus on ‘Sarb-Oxing’ and the 
attention given to the internal control environment for non-financial indicators is 
especially innovative and ambitious. 
 
In assessing Novo Nordisk’s approach to sustainability, an important distinction 
between integration and embedding may be drawn, in the sense that we may consider 
integration as an assemblage of largely administrative processes, which may in turn 
bring about more substantive institutional change in terms of the embedding of 
sustainability within the organization. At the day-to-day operational level, there was 
recognition on the part of senior management that this dimension of organizational 
change may be more difficult to assess:  
 
“I can argue that what we do here with TBL management is driving employee 
motivation. Can I prove it? Probably not. But I can hypothesise, I can make 
the argument, and then it’s up to you to disprove it.” (Vice-President, Global 
TBL Management) 
 
However, whilst the importance of employee motivation to the company’s overall 
strategy was clearly recognized, the wider challenge facing managers (and the 
company as a whole) in adopting a sustainability ‘mindset’ within a patient-focused 
commercial environment was also acknowledged: 
 
“Sustainability is never the only thing you’re thinking about. The biggest 
objective of this company is better medical treatment. And, for example, for 
those people who have to inject insulin 15 minutes before they can eat in a 
restaurant, convenience is a huge part of making sure that they can manage 
their disease properly. And, it’s about how you manage that. How do you 
balance that convenience with the environmental issues of the tools they need 
to get their treatment? So, it’s about the priorities of the company. Can 
environmental issues really be the most important factor for a company that 
is really about healthcare?” (Director, Global TBL Management). 
 
On a practical level, the difficulties facing Novo Nordisk in embedding sustainability 
are especially evident in relation to the company’s focus on qualitative and cultural 
dimensions of management in the form of stated values and fundamentals. The 
facilitation process represents a highly unusual formal control mechanism to measure 
the extent to which business units, and the organization as a whole, ‘complies’ with 
the values and principles set out in the company charter. In defining a benchmark for 
the underlying managerial ‘mindset’ within the organization, we may regard this 
dimension of corporate behaviour as potentially very significant in the context of 
attempts to embed sustainability.  
 
By comparison with the language used in the company’s commitments and values, it 
is perhaps surprising that the principles defined in the company charter do not 
explicitly mention or embody sustainability. Indeed, whilst the formal control systems 
developed at Novo Nordisk provide a broad and potentially useful approach to 
establish and manage a sustainability strategy, there nevertheless remains a number of 
equally important, but less visible, informal dimensions relevant to the embedding of 
a sustainability ‘mindset’ within the organization. For example, the operation of the 
formal control systems, and the success of the wider objective of full integration, 
remains dependent on the belief and commitment of the staff involved to work 
together to solve problems.  In the case of ‘Sarb-Oxing’ for example, the application 
of a strict financial control systems environment to non-financial indicators was not 
just a technically complex task, but also involved a remarkable level of collaboration 
and collective action between staff across a number of different departments where 
one might normally expect to find barriers and obstacles in the way. Likewise, the 
role of the TBL management forum is crucial in creating a collaborative approach to 
managing sustainability where different functional areas of the business can share 
experiences and feed into the development process. 
 
More generally, employees in the company’s Danish headquarters appeared to be 
genuinely comfortable with an emphasis on both quantitative and qualitative aspects 
of performance measurement and management control. Rather than feeling 
resentment at being ‘policed’ by the facilitation process, staff appeared united by such 
mechanisms and collectively geared towards common organizational aims. It was 
argued by some Novo Nordisk managers that there was in general a deep-rooted and 
values-based culture in Danish business units that might not be so obvious or 
prevalent elsewhere in the global company, as well as a widespread assumption that 
sustainability is simply ‘the right thing to do’:  
 
“The Scandinavian mindset is very transparent and honest. People come to 
you with a concern and it’s like “Oh! That’s a valid concern and we should do 
something”. And there are lots of companies that just wouldn’t have such a 
reaction” (Director, Global TBL Management). 
 
Managing this in the context of global growth presents a particular challenge for 
Novo Nordisk: 
 
“We are a Danish company and we have a global presence. But there is a 
difference between being a Danish company with a global presence and being 
a global company” (Director, Global TBL Management). 
 
Over the last two decades, Novo Nordisk has gradually developed a more pro-active 
form of stakeholder engagement that has shaped its strategic management of 
sustainability. In addition, it has created a set of control systems to measure the 
company’s performance against its stated social and environmental commitments, and 
has sought to move closer to full integration. Formal control systems, and the use of 
quantitative performance indicators, are clearly useful in this context, and Novo 
Nordisk’s ongoing efforts to improve the rigour and sophistication of its internal non-
financial control environment are undoubtedly world leading. However, beyond the 
development of integrated systems based on quantitative non-financial indicators, a 
particularly welcome dimension of Novo Nordisk’s approach is its recognition of the 
importance of managing values and principles as well as more tangible commitments 
and outcomes. In fostering the kind of ‘mindset’ that many regard as being essential 
to embedding sustainability in the organization, this is arguably a very useful 
mechanism, with broad appeal, whose potential is in our view still largely untapped.  
 
 
 
 
 
